EFFICACY OF FINE NEEDLE ASPIRATION CYTOLOGY (FNAC) IN THE DIAGNOSIS OF TUBERCULOUS LYMPHADENITIS AS COMPARED TO GENEXPERT IN A TERTIARY CARE HOSPITAL, PUNJAB, PAKISTAN
Main Article Content
Keywords
Tuberculous Lymphadenitis, FNAC, GeneXpert MTB/RIF
Abstract
Background and Objectives
Tuberculous lymphadenitis is a common extrapulmonary manifestation of tuberculosis which is difficult to accurately diagnose especially when resources are limited like in most of the progressive countries. The current research is focused on comparing the diagnostic utility and effectiveness of GeneXpert and Fine Needle Aspiration Cytology (FNAC) for accurate identification of tuberculous lymphadenitis.
Materials & Methods
This study was conducted at a tertiary care hospital, Punjab, Pakistan, from October 2022 to December 2023. A total of 150 patients with clinically suspected tuberculous lymphadenitis were included. FNAC and GeneXpert were performed on all patients in the study and the results were compared for accuracy of diagnosis. FANC results were analyzed for granulomatous inflammation and AFB presence. On the other hand, GeneXpert was used to detect Mycobacterium TB DNA and rifampicin resistance.
Results
FNAC identified granulomatous inflammation in 80% of cases. Sensitivity and specificity of FNAC remains 92.3% and 66.7% respectively. However, GeneXpert showed a sensitivity of 86.7% and detected rifampicin resistance in 10% of cases.
Conclusion
This comparative study concluded that although FNAC is initially a valueable tool for diagnosing tuberculous lymphadenitis, limitations in accuracy limits its reliability. However, the other diagnostic tool, GeneXpert provides comparatively higher diagnostic accuracy and is essential for detecting drug resistance. Therefore, this study recommends an integrated use of FNAC and GeneXpert to improve the diagnosis of Tuberculous lymphadenitis.
References
[2]. Das DK. Fine-needle aspiration cytology in the diagnosis of tuberculous lesions. Lab Med. 2000;31(11):625-632 https://doi.org/10.1309/UJ0B-VDWV-U0LE-E0QQ.
[3]. Knox J, Lane G, Wong J, Trevan P, Karunajeewa H. Diagnosis of tuberculous lymphadenitis using fine needle aspiration biopsy. Internal medicine journal. 2012;42(9):1029–36 DOI: 10.1111/j.1445-5994.2012.02748.x.
[4]. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005-1015 DOI: 10.1056/NEJMoa0907847.
[5]. Gómez AV, González-Martín J, García-Basteiro AL. Xpert® MTB/RIF: Usefulness for the diagnosis of tuberculosis and resistance to rifampicin. Medicina Clínica (English Edition). 2017;149(9):399–405 https://doi.org/10.1016/j.medcle.2017.09.021.
[6]. World Health Organization (WHO). Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement. Geneva: WHO; 2011.
[7]. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2014;44(2):435-446 DOI: 10.1183/09031936.00007814.
[8]. Handa U, Mundi I, Mohan H. Nodal tuberculosis revisited: A review. J Infect Dev Ctries. 2012;6(1):6-12 DOI: https://doi.org/10.3855/jidc.2090.
[9]. Moure R, Muñoz L, Torres M, Santín M, Martín R, Alcaide F. Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. J Clin Microbiol. 2011;49(3):1137-1139 DOI: 10.1128/JCM.01831-10.
[10]. Sharma SK, Ryan H, Khaparde S, Sachdeva KS, Singh AD, Mohan A, et al. Index-TB guidelines: Guidelines on extrapulmonary tuberculosis for India. Indian J Med Res. 2017;145(4):448-463 doi: 10.4103/ijmr.IJMR_1950_16.
[11]. Purohit MR, Mustafa T, Mørkve O, Sviland L. Gender differences in the clinical diagnosis of tuberculous lymphadenitis—a hospital-based study from Central India. Int J Infect Dis. 2009;13(5):600-605 https://doi.org/10.1016/j.ijid.2008.06.046.
[12]. Tortoli E, Russo C, Piersimoni C, Mazzola E, Dal Monte P, Pascarella M, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J. 2012;40(2):442-447 DOI: 10.1183/09031936.00176311.
[13]. Norbis L, Alagna R, Tortoli E, Codecasa LR, Migliori GB, Cirillo DM. Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis. Expert Rev Anti Infect Ther. 2014;12(5):633-647 DOI: 10.1586/14787210.2014.899900.
[14]. van Kampen SC, Anthony RM, Kazi M, Peters R, Ramsay AR, Justesen US, et al. Xpert MTB/RIF version G4 assay for tuberculosis testing in a low tuberculosis incidence setting. Eur Respir J. 2017;49(3):1602216 DOI: https://doi.org/10.1186/s12879-016-2039-4.
[15]. Pietersen E, Ignatius E, Streicher EM, Mastrapa B, Padanilam X, Pooran A, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014;383(9924):1230-1239 DOI: 10.1016/S0140-6736(13)62675-6.
[16]. Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV burden. Int J Tuberc Lung Dis. 2014;18(8):932-937 DOI: 10.1371/journal.pmed.1001760.
[17]. Yang ZG, Kong YY, Gao GP, Bai HG, Cai YJ, Zhang CP. Diagnostic Accuracy of the Xpert MTB/RIF Assay for Lymph Node Tuberculosis: A Systematic Review and Meta-Analysis. Pathol Res Pract. 2018;214(7):977-982 doi: 10.1155/2019/4878240.
[18]. Parsons LM, Somoskövi Á, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev. 2011;24(2):314-350 DOI: 10.1128/CMR.00059-10.
[19]. Pimkina E, Zablockis R, Nikolayevskyy V, Danila E, Davidaviciene E. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania. Respiratory medicine. 2015;109(11):1484–9 DOI: 10.1016/j.rmed.2015.07.006.
[20]. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J. 2016;48(2):516-525 DOI: 10.1183/13993003.00543-2016.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Azra Akhtar
Consultant Histopathology and Cytopathology, Buch International Hospital, Multan, Pakistan
Asmah Afzal
Assistant Professor, Department of Pathology, Quaid-e-Azam Medical College Bahawalpur, Pakistan.
Sadaf Shafique
Associate Professor, Department of Pathology, Quaid-e-Azam Medical College, Bahawalpur
Fatima Khalid
Senior Demonstrator, Department of Pathology, Al Aleem Medical College, Lahore, Pakistan
Firdous Iqbal
Assistant Professor, University of Health Sciences, Lahore, Pakistan